Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 9500 (miR-9500) is a small, non-coding RNA molecule approximately 70 nucleotides in length, processed to a 19-nucleotide mature sequence, transcribed from an intergenic region on human chromosome 3. It functions as a post-transcriptional regulator by binding to the 3’-UTR of specific mRNA targets, notably Akt1, leading to decreased translation of the protein without affecting mRNA levels. MiR-9500 is downregulated in human lung cancer cells and tissues, and experimental upregulation of miR-9500 suppresses cell proliferation, cell cycle progression, migration, tumorigenesis, and metastasis in lung cancer models, largely by targeting the PI3K/Akt signaling pathway. This makes miR-9500 a proposed tumor suppressor in lung cancer and a candidate for therapeutic investigation.
Suppression of target gene (Akt1) translation via direct interaction with 3’-UTR of mRNA
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 9500 (miR-9500).